Cancer Detection and Treatment: The Role of Nanomedicines

Nanotechnology is a field which has been at the forefront of research over the past two decades. The full potential of nanotechnology has yet to be fully realized. One subset of nanotechnology that has emerged is nanomedicine, which has been able to exploit the unique properties of nano-sized particles for therapeutics. Nanomedicine has the potential to increase the specific treatment of cancer cells while leaving healthy cells intact through the use of novel nanoparticles to seek and treat cancer in the human body. However, there are undoubtedly toxicities, which have not yet been fully elucidated. Various nano-carriers such as nanoshells, nanocrystals, nanopolymers, quantum dots, and dendrimers, and their role in early cancer detection and treatment have been discussed in this article.

[1]  F. Esteva,et al.  Her2-positive breast cancer: herceptin and beyond. , 2008, European journal of cancer.

[2]  Shaker A Mousa,et al.  Emerging nanopharmaceuticals. , 2008, Nanomedicine : nanotechnology, biology, and medicine.

[3]  Ralph Weissleder,et al.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.

[4]  J. B. Loefer.  Growth of sarcoma in hypophysectomized rats , 1952, Cancer.

[5]  Michele Follen,et al.  Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. , 2003, Cancer research.

[6]  M. Delano,et al.  Emerging implications of nanotechnology on cancer diagnostics and therapeutics , 2006, Cancer.

[7]  Michael Hawkins,et al.  Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) , 2005, Clinical Cancer Research.

[8]  H. Rothuizen,et al.  Translating biomolecular recognition into nanomechanics. , 2000, Science.

[9]  D. Patel,et al.  Clinical Use of Anti‐Epidermal Growth Factor Receptor Monoclonal Antibodies in Metastatic Colorectal Cancer , 2008, Pharmacotherapy.

[10]  Shiladitya Sengupta,et al.  Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system , 2005, Nature.

[11]  Vladimir P Torchilin,et al.  Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo , 2005, Nature Medicine.

[12]  Iftach Yacoby,et al.  Targeted Drug-Carrying Bacteriophages as Antibacterial Nanomedicines , 2007, Antimicrobial Agents and Chemotherapy.

[13]  G. Kwon,et al.  Polymeric micelles for delivery of poorly water-soluble compounds. , 2003, Critical reviews in therapeutic drug carrier systems.

[14]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[15]  Xiaohua Huang,et al.  Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. , 2006, Cancer letters.

[16]  R. Lerner,et al.  A cell-penetrating peptide from a novel pVII-pIX phage-displayed random peptide library. , 2002, Bioorganic & medicinal chemistry.

[17]  Igor L. Medintz,et al.  Quantum dot bioconjugates for imaging, labelling and sensing , 2005, Nature materials.

[18]  S. Gettinger.  Targeted therapy in advanced non-small-cell lung cancer. , 2008, Seminars in respiratory and critical care medicine.

[19]  Kazunori Kataoka,et al.  Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. , 2006, Pharmacology & therapeutics.

[20]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Bruchez,et al.  Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots , 2003, Nature Biotechnology.

[22]  T. Xu,et al.  Pharmaceutical applications of dendrimers: promising nanocarriers for drug delivery. , 2008, Frontiers in bioscience : a journal and virtual library.

[23]  Edith A Perez,et al.  Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. , 2005, Future oncology.

[24]  S. Bhatia,et al.  Probing the Cytotoxicity Of Semiconductor Quantum Dots. , 2004, Nano letters.

[25]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[26]  Rakesh K Jain,et al.  Antiangiogenic therapy for cancer: current and emerging concepts. , 2005, Oncology.

[27]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[28]  Erkki Ruoslahti,et al.  Nanocrystal targeting in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Leon Hirsch,et al.  Nanoshell-Enabled Photonics-Based Imaging and Therapy of Cancer , 2004, Technology in cancer research & treatment.

[30]  T. Xu,et al.  Design, synthesis and potent pharmaceutical applications of glycodendrimers: a mini review. , 2007, Current drug discovery technologies.

[31]  F. Marshall,et al.  In vivo molecular and cellular imaging with quantum dots. , 2005, Current opinion in biotechnology.

[32]  T. Thundat,et al.  Bioassay of prostate-specific antigen (PSA) using microcantilevers , 2001, Nature Biotechnology.

[33]  J. Post,et al.  Quantum dot ligands provide new insights into erbB/HER receptor–mediated signal transduction , 2004, Nature Biotechnology.

[34]  A. C. Hunter,et al.  Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  J. West,et al.  Immunotargeted nanoshells for integrated cancer imaging and therapy. , 2005, Nano letters.

[36]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[37]  A. Majumdar,et al.  Cantilever arrays for multiplexed mechanical analysis of biomolecular reactions. , 2004, Mechanics & chemistry of biosystems : MCB.

[38]  R. Sasisekharan,et al.  Exploiting nanotechnology to target cancer , 2007, British Journal of Cancer.

[39]  I. Yacoby,et al.  Killing cancer cells by targeted drug-carrying phage nanomedicines , 2008, BMC biotechnology.

[40]  Y. Liu,et al.  Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery. , 2007, Molecular pharmaceutics.

[41]  R. Skalak,et al.  Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. , 1995, Cancer research.

[42]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[43]  Shuming Nie,et al.  Multicolor quantum dots for molecular diagnostics of cancer , 2006, Expert review of molecular diagnostics.

[44]  R. Stafford,et al.  Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Bradford G Orr,et al.  Direct observation of lipid bilayer disruption by poly(amidoamine) dendrimers. , 2004, Chemistry and physics of lipids.

[46]  R Weissleder,et al.  Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties , 1993, Magnetic resonance in medicine.

[47]  Jun Fang,et al.  Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. , 2003, International immunopharmacology.

[48]  K. Kono,et al.  Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. , 2000, Bioconjugate chemistry.

[49]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  W. D. de Jong,et al.  Drug delivery and nanoparticles: Applications and hazards , 2008, International journal of nanomedicine.

[51]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[52]  John W. Park.  Liposome-based drug delivery in breast cancer treatment , 2002, Breast Cancer Research.

[53]  Shuming Nie,et al.  Emerging use of nanoparticles in diagnosis and treatment of breast cancer. , 2006, The Lancet. Oncology.